Frontiers in Cell and Developmental Biology · 2021 · 19 citations · 43 references
Life SciencesMolecular BiologyOncologyDna RepairMolecular Cell BiologyMolecular OncologyChromatinDna Damage SignalingDna Double-strand Break RepairDna Strand BreaksDouble-strand Break RepairReplication Stress ResponseAtr ActivationDna Damage Response PathwaysDna Damage ResponsesDna Double-strand BreaksDna Single-strand BreaksGamma-h2ax SignalingSingle-strand Dna Breaksγ-H2ax Foci Formation
The maintenance of genome integrity and fidelity is vital for the proper function and survival of all organisms. Recent studies have revealed that APE2 is required to activate an ATR-Chk1 DNA damage response (DDR) pathway in response to oxidative stress and a defined DNA single-strand break (SSB) in Xenopus laevis egg extracts. However, it remains unclear whether APE2 is a general regulator of the DDR pathway in mammalian cells. Here, we provide evidence using human pancreatic cancer cells that APE2 is essential for ATR DDR pathway activation in response to different stressful conditions including oxidative stress, DNA replication stress, and DNA double-strand breaks. Fluorescence microscopy analysis shows that APE2-knockdown (KD) leads to enhanced γH2AX foci and increased micronuclei formation. In addition, we identified a small molecule compound Celastrol as an APE2 inhibitor that specifically compromises the binding of APE2 but not RPA to ssDNA and 3′-5′ exonuclease activity of APE2 but not APE1. The impairment of ATR-Chk1 DDR pathway by Celastrol in Xenopus egg extracts and human pancreatic cancer cells highlights the physiological significance of Celastrol in the regulation of APE2 functionalities in genome integrity. Notably, cell viability assays demonstrate that APE2-KD or Celastrol sensitizes pancreatic cancer cells to chemotherapy drugs. Overall, we propose APE2 as a general regulator for the DDR pathway in genome integrity maintenance.
43
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +14